MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

Search

Grifols SA

Abierto

SectorFinanzas

8.652 -7.09

Resumen

Variación precio

24h

Actual

Mínimo

8.326

Máximo

9.308

Métricas clave

By Trading Economics

Ingresos

17M

69M

Ventas

183M

2B

P/B

Media del Sector

45.229

22.015

BPA

0.101

Margen de beneficio

3.491

Empleados

23,833

EBITDA

57M

482M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+72.24% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

3.3B

6.8B

Apertura anterior

15.74

Cierre anterior

8.652

Noticias sobre sentimiento de mercado

By Acuity

65%

35%

484 / 542 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Grifols SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 abr 2025, 17:19 UTC

Adquisiciones, fusiones, absorciones

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 abr 2025, 13:02 UTC

Adquisiciones, fusiones, absorciones

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 abr 2025, 10:13 UTC

Adquisiciones, fusiones, absorciones

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 jul 2024, 10:40 UTC

Adquisiciones, fusiones, absorciones

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 jul 2024, 09:13 UTC

Adquisiciones, fusiones, absorciones

Grifols Faces Delisting Bid From Founding Family and Brookfield

2 abr 2025, 09:27 UTC

Acciones populares

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Comparación entre iguales

Cambio de precio

Grifols SA Esperado

Precio Objetivo

By TipRanks

72.24% repunte

Estimación a 12 meses

Media 14.02 EUR  72.24%

Máximo 19.05 EUR

Mínimo 11 EUR

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Grifols SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.152 / 8.574Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

484 / 542 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.